Thus far only two studies have considered OPTN in PD; a paper from Osawa and colleagues who immunostained for OPTN in patients with PD and our previous report considering OPTN expression, puncta, and colocalization with LC3 in the same rat rotenone model we used here (Osawa et al., 2011; Wise and Cannon, 2016). This evidence concerns the gene MAP1LC3A and Parkinson disease.